VERACYTE, INC.·4

Dec 8, 4:34 PM ET

EASTHAM KARIN 4

4 · VERACYTE, INC. · Filed Dec 8, 2025

Insider Transaction Report

Form 4
Period: 2025-12-05
Transactions
  • Exercise/Conversion

    Common Stock

    2025-12-05$7.94/sh+10,000$79,40023,554 total
  • Sale

    Common Stock

    2025-12-05$44.52/sh6,392$284,57127,162 total
  • Sale

    Common Stock

    2025-12-05$45.84/sh12,808$587,08014,354 total
  • Sale

    Common Stock

    2025-12-05$46.59/sh800$37,27213,554 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2025-12-0510,0000 total
    Exercise: $7.94Exp: 2027-06-07Common Stock (10,000 underlying)
Footnotes (5)
  • [F1]The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 5, 2025.
  • [F2]Represents weighted average sales price. Sale prices for the transactions range from $44.22 to $44.91. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
  • [F3]Represents weighted average sales price. Sale prices for the transactions range from $45.28 to $46.27. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
  • [F4]Represents weighted average sales price. Sale prices for the transactions range from $46.32 to $46.98. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
  • [F5]The option is fully vested.

Documents

1 file
  • 4
    wk-form4_1765229667.xmlPrimary

    FORM 4